CAREDX INC (CDNA) Fundamental Analysis & Valuation

NASDAQ:CDNA • US14167L1035

Current stock price

21.5 USD
+0.69 (+3.32%)
At close:
21.9 USD
+0.4 (+1.86%)
After Hours:

This CDNA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CDNA Profitability Analysis

1.1 Basic Checks

  • CDNA had positive earnings in the past year.
  • In the past year CDNA had a positive cash flow from operations.
  • In the past 5 years CDNA reported 4 times negative net income.
  • In multiple years CDNA reported negative operating cash flow during the last 5 years.
CDNA Yearly Net Income VS EBIT VS OCF VS FCFCDNA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -5.17%, CDNA belongs to the top of the industry, outperforming 84.08% of the companies in the same industry.
  • CDNA's Return On Equity of -7.05% is amongst the best of the industry. CDNA outperforms 87.57% of its industry peers.
Industry RankSector Rank
ROA -5.17%
ROE -7.05%
ROIC N/A
ROA(3y)-11.74%
ROA(5y)-10.95%
ROE(3y)-21.99%
ROE(5y)-18.07%
ROIC(3y)N/A
ROIC(5y)N/A
CDNA Yearly ROA, ROE, ROICCDNA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 400 600 800

1.3 Margins

  • CDNA has a Gross Margin of 67.55%. This is in the better half of the industry: CDNA outperforms 78.83% of its industry peers.
  • CDNA's Gross Margin has been stable in the last couple of years.
  • CDNA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.55%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.22%
GM growth 5Y0.11%
CDNA Yearly Profit, Operating, Gross MarginsCDNA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. CDNA Health Analysis

2.1 Basic Checks

  • CDNA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CDNA has less shares outstanding
  • The number of shares outstanding for CDNA has been increased compared to 5 years ago.
  • CDNA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
CDNA Yearly Shares OutstandingCDNA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M
CDNA Yearly Total Debt VS Total AssetsCDNA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • An Altman-Z score of 4.54 indicates that CDNA is not in any danger for bankruptcy at the moment.
  • CDNA has a better Altman-Z score (4.54) than 72.82% of its industry peers.
  • There is no outstanding debt for CDNA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 4.54
ROIC/WACCN/A
WACC9.52%
CDNA Yearly LT Debt VS Equity VS FCFCDNA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M 200M 300M 400M

2.3 Liquidity

  • CDNA has a Current Ratio of 2.86. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
  • With a Current ratio value of 2.86, CDNA is not doing good in the industry: 64.47% of the companies in the same industry are doing better.
  • CDNA has a Quick Ratio of 2.56. This indicates that CDNA is financially healthy and has no problem in meeting its short term obligations.
  • CDNA has a Quick ratio of 2.56. This is in the lower half of the industry: CDNA underperforms 66.99% of its industry peers.
Industry RankSector Rank
Current Ratio 2.86
Quick Ratio 2.56
CDNA Yearly Current Assets VS Current LiabilitesCDNA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. CDNA Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 27.27% over the past year.
  • The Earnings Per Share has been growing by 21.81% on average over the past years. This is a very strong growth
  • CDNA shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 13.79%.
  • Measured over the past years, CDNA shows a quite strong growth in Revenue. The Revenue has been growing by 14.59% on average per year.
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5Y21.81%
EPS Q2Q%277.78%
Revenue 1Y (TTM)13.79%
Revenue growth 3Y5.68%
Revenue growth 5Y14.59%
Sales Q2Q%38.99%

3.2 Future

  • CDNA is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 41.02% yearly.
  • CDNA is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 12.14% yearly.
EPS Next Y21.09%
EPS Next 2Y37.04%
EPS Next 3Y41.02%
EPS Next 5YN/A
Revenue Next Year15.29%
Revenue Next 2Y13.28%
Revenue Next 3Y12.14%
Revenue Next 5YN/A

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
CDNA Yearly Revenue VS EstimatesCDNA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 100M 200M 300M 400M 500M
CDNA Yearly EPS VS EstimatesCDNA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 1 -1 1.5

More info and screens

Find the best growth stocksShow best growing peers

5

4. CDNA Valuation Analysis

4.1 Price/Earnings Ratio

  • CDNA is valuated quite expensively with a Price/Earnings ratio of 25.60.
  • Based on the Price/Earnings ratio, CDNA is valued cheaper than 92.04% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 26.64. CDNA is around the same levels.
  • With a Price/Forward Earnings ratio of 19.40, CDNA is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of CDNA indicates a rather cheap valuation: CDNA is cheaper than 94.76% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of CDNA to the average of the S&P500 Index (21.36), we can say CDNA is valued inline with the index average.
Industry RankSector Rank
PE 25.6
Fwd PE 19.4
CDNA Price Earnings VS Forward Price EarningsCDNA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

  • Based on the Price/Free Cash Flow ratio, CDNA is valued cheaply inside the industry as 93.98% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 31.07
EV/EBITDA N/A
CDNA Per share dataCDNA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6

4.3 Compensation for Growth

  • CDNA's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • A more expensive valuation may be justified as CDNA's earnings are expected to grow with 41.02% in the coming years.
PEG (NY)1.21
PEG (5Y)1.17
EPS Next 2Y37.04%
EPS Next 3Y41.02%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CDNA Dividend Analysis

5.1 Amount

  • CDNA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CDNA Fundamentals: All Metrics, Ratios and Statistics

CAREDX INC

NASDAQ:CDNA (5/1/2026, 8:14:36 PM)

After market: 21.9 +0.4 (+1.86%)

21.5

+0.69 (+3.32%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Industry Strength55.9
Industry Growth13.04
Earnings (Last)04-28
Earnings (Next)08-04
Inst Owners101.86%
Inst Owner Change-0.07%
Ins Owners3.13%
Ins Owner Change3.61%
Market Cap1.10B
Revenue(TTM)379.81M
Net Income(TTM)-21.35M
Analysts78.67
Price Target25.67 (19.4%)
Short Float %13.07%
Short Ratio9.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)21.48%
Min EPS beat(2)-50.8%
Max EPS beat(2)93.77%
EPS beat(4)2
Avg EPS beat(4)15.23%
Min EPS beat(4)-50.8%
Max EPS beat(4)93.77%
EPS beat(8)6
Avg EPS beat(8)215.83%
EPS beat(12)10
Avg EPS beat(12)155.22%
EPS beat(16)12
Avg EPS beat(16)110.77%
Revenue beat(2)2
Avg Revenue beat(2)2.95%
Min Revenue beat(2)2.92%
Max Revenue beat(2)2.98%
Revenue beat(4)2
Avg Revenue beat(4)-0.48%
Min Revenue beat(4)-6.22%
Max Revenue beat(4)2.98%
Revenue beat(8)6
Avg Revenue beat(8)5.63%
Revenue beat(12)9
Avg Revenue beat(12)6.29%
Revenue beat(16)9
Avg Revenue beat(16)3.99%
PT rev (1m)4.86%
PT rev (3m)4.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-37.14%
EPS NY rev (1m)-2.78%
EPS NY rev (3m)-23.04%
Revenue NQ rev (1m)1.67%
Revenue NQ rev (3m)3.56%
Revenue NY rev (1m)0%
Revenue NY rev (3m)3.57%
Valuation
Industry RankSector Rank
PE 25.6
Fwd PE 19.4
P/S 2.9
P/FCF 31.07
P/OCF 26.2
P/B 3.63
P/tB 4.77
EV/EBITDA N/A
EPS(TTM)0.84
EY3.91%
EPS(NY)1.11
Fwd EY5.15%
FCF(TTM)0.69
FCFY3.22%
OCF(TTM)0.82
OCFY3.82%
SpS7.42
BVpS5.92
TBVpS4.51
PEG (NY)1.21
PEG (5Y)1.17
Graham Number10.5756 (-50.81%)
Profitability
Industry RankSector Rank
ROA -5.17%
ROE -7.05%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.55%
FCFM 9.33%
ROA(3y)-11.74%
ROA(5y)-10.95%
ROE(3y)-21.99%
ROE(5y)-18.07%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.22%
GM growth 5Y0.11%
F-Score6
Asset Turnover0.92
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA N/A
Cap/Depr 43.87%
Cap/Sales 1.73%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.86
Quick Ratio 2.56
Altman-Z 4.54
F-Score6
WACC9.52%
ROIC/WACCN/A
Cap/Depr(3y)51.26%
Cap/Depr(5y)118.75%
Cap/Sales(3y)2.32%
Cap/Sales(5y)4.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)27.27%
EPS 3YN/A
EPS 5Y21.81%
EPS Q2Q%277.78%
EPS Next Y21.09%
EPS Next 2Y37.04%
EPS Next 3Y41.02%
EPS Next 5YN/A
Revenue 1Y (TTM)13.79%
Revenue growth 3Y5.68%
Revenue growth 5Y14.59%
Sales Q2Q%38.99%
Revenue Next Year15.29%
Revenue Next 2Y13.28%
Revenue Next 3Y12.14%
Revenue Next 5YN/A
EBIT growth 1Y57.32%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year38.1%
EBIT Next 3Y43.44%
EBIT Next 5YN/A
FCF growth 1Y12.29%
FCF growth 3YN/A
FCF growth 5Y8.97%
OCF growth 1Y10.47%
OCF growth 3YN/A
OCF growth 5Y4.69%

CAREDX INC / CDNA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CAREDX INC (CDNA) stock?

ChartMill assigns a fundamental rating of 5 / 10 to CDNA.


What is the valuation status of CAREDX INC (CDNA) stock?

ChartMill assigns a valuation rating of 5 / 10 to CAREDX INC (CDNA). This can be considered as Fairly Valued.


How profitable is CAREDX INC (CDNA) stock?

CAREDX INC (CDNA) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for CDNA stock?

The Earnings per Share (EPS) of CAREDX INC (CDNA) is expected to grow by 21.09% in the next year.